EAM
VRTX icon

Eagle Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Eagle Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.2M Buy
8,119
+1,440
+22% +$692K 0.02% 405
2024
Q2 		$3.15M Buy
6,679
+814
+14% +$353K 0.02% 434
2024
Q1 		$2.47M Sell
5,865
-243
-4% -$103K 0.01% 460
2023
Q4 		$2.49M Sell
6,108
-977
-14% -$361K 0.01% 435
2023
Q3 		$2.46M Sell
7,085
-280
-4% -$97.9K 0.01% 418
2023
Q2 		$2.59M Buy
7,365
+643
+10% +$217K 0.01% 423
2023
Q1 		$2.12M Buy
+6,722
New +$2.02M 0.01% 435
2016
Q2 		– Sell
-98,933
Closed -$7.86M – 656
2016
Q1 		$7.86M Buy
98,933
+7,634
+8% +$691K 0.05% 347
2015
Q4 		$11.5M Buy
91,299
+9,494
+12% +$1.15M 0.08% 316
2015
Q3 		$8.52M Buy
81,805
+10,021
+14% +$1.29M 0.06% 345
2015
Q2 		$8.86M Buy
71,784
+3,067
+4% +$386K 0.05% 348
2015
Q1 		$8.11M Buy
68,717
+213
+0.3% +$25.5K 0.05% 362
2014
Q4 		$8.14M Buy
68,504
+2,208
+3% +$249K 0.05% 353
2014
Q3 		$7.45M Buy
+66,296
New +$6.31M 0.04% 371
2013
Q4 		– Sell
-353,623
Closed -$26.9M – 662
2013
Q3 		$26.9M Buy
353,623
+408
+0.1% +$32.5K 0.13% 202
2013
Q2 		$28.3M Buy
+353,215
New +$26M 0.19% 171

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Eagle Asset Management's VRTX Position: Q3 2024 in Review

Eagle Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 22% in Q3 2024, buying an estimated $692K and bringing the position to 8,119 shares worth $4.2M. The position accounts for 0.02% of the portfolio, ranked #405.

Eagle Asset Management first reported a position in VRTX in Q2 2013 and has held it in 16 quarters since. The position peaked at $28.3M in Q2 2013. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Eagle Asset Management held 8,119 shares of Vertex Pharmaceuticals worth $4.2M as of Q3 2024.
  • Eagle Asset Management bought 1,440 Vertex Pharmaceuticals shares in Q3 2024, an estimated $692K.
  • Vertex Pharmaceuticals made up 0.02% of Eagle Asset Management's portfolio in Q3 2024, its #405 holding.
  • Eagle Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • Eagle Asset Management's Vertex Pharmaceuticals position peaked at $28.3M in Q2 2013.
  • 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.